Quince Therapeutics (QNCX) Competitors $1.78 +0.02 (+1.14%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends QNCX vs. TRVI, ETON, CGC, AQST, TNGX, SAGE, JSPR, VALN, FDMT, and CCCCShould you be buying Quince Therapeutics stock or one of its competitors? The main competitors of Quince Therapeutics include Trevi Therapeutics (TRVI), Eton Pharmaceuticals (ETON), Canopy Growth (CGC), Aquestive Therapeutics (AQST), Tango Therapeutics (TNGX), Sage Therapeutics (SAGE), Jasper Therapeutics (JSPR), Valneva (VALN), 4D Molecular Therapeutics (FDMT), and C4 Therapeutics (CCCC). These companies are all part of the "pharmaceutical products" industry. Quince Therapeutics vs. Trevi Therapeutics Eton Pharmaceuticals Canopy Growth Aquestive Therapeutics Tango Therapeutics Sage Therapeutics Jasper Therapeutics Valneva 4D Molecular Therapeutics C4 Therapeutics Quince Therapeutics (NASDAQ:QNCX) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, community ranking, valuation, dividends, risk and institutional ownership. Does the media favor QNCX or TRVI? In the previous week, Quince Therapeutics had 8 more articles in the media than Trevi Therapeutics. MarketBeat recorded 10 mentions for Quince Therapeutics and 2 mentions for Trevi Therapeutics. Quince Therapeutics' average media sentiment score of 0.67 beat Trevi Therapeutics' score of 0.00 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer QNCX or TRVI? Quince Therapeutics presently has a consensus target price of $8.67, indicating a potential upside of 386.89%. Trevi Therapeutics has a consensus target price of $9.31, indicating a potential upside of 129.94%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Quince Therapeutics is more favorable than Trevi Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40Trevi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20 Does the MarketBeat Community prefer QNCX or TRVI? Trevi Therapeutics received 89 more outperform votes than Quince Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Quince Therapeutics an outperform vote while only 65.28% of users gave Trevi Therapeutics an outperform vote. CompanyUnderperformOutperformQuince TherapeuticsOutperform Votes5100.00% Underperform VotesNo VotesTrevi TherapeuticsOutperform Votes9465.28% Underperform Votes5034.72% Do insiders and institutionals have more ownership in QNCX or TRVI? 30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 16.8% of Quince Therapeutics shares are held by company insiders. Comparatively, 24.4% of Trevi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has preferable earnings and valuation, QNCX or TRVI? Trevi Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuince TherapeuticsN/AN/A-$31.39M-$1.24-1.44Trevi TherapeuticsN/AN/A-$29.07M-$0.44-9.20 Which has more volatility and risk, QNCX or TRVI? Quince Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Is QNCX or TRVI more profitable? Quince Therapeutics' return on equity of -53.27% beat Trevi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Quince TherapeuticsN/A -53.27% -22.73% Trevi Therapeutics N/A -63.31%-57.06% SummaryQuince Therapeutics beats Trevi Therapeutics on 8 of the 15 factors compared between the two stocks. Ad DTICackling Kamala hates this companyDo you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution. Before that happens, you need to see the details here. Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNCX vs. The Competition Export to ExcelMetricQuince TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$78.32M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E Ratio-1.4446.7389.9717.18Price / SalesN/A415.011,116.21116.99Price / CashN/A182.1042.8937.86Price / Book0.903.894.784.78Net Income-$31.39M-$42.21M$120.23M$225.60M7 Day Performance-12.32%-2.15%-1.92%-1.23%1 Month Performance-14.42%4.20%11.49%3.36%1 Year Performance63.30%18.39%30.57%16.60% Quince Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNCXQuince Therapeutics2.8954 of 5 stars$1.78+1.1%$8.67+386.9%+60.4%$78.32MN/A-1.4460Analyst ForecastAnalyst RevisionNews CoverageTRVITrevi Therapeutics3.0363 of 5 stars$4.34+4.1%$9.31+114.6%+214.0%$333.62MN/A-10.2020Gap DownHigh Trading VolumeETONEton Pharmaceuticals2.1328 of 5 stars$12.91+4.5%$15.00+16.2%+176.9%$333.59M$31.64M-56.1420CGCCanopy Growth2.4368 of 5 stars$3.05-1.9%$3.50+14.8%-41.0%$332.27M$220.27M-0.631,029Analyst RevisionNews CoverageAQSTAquestive Therapeutics1.495 of 5 stars$3.61flat$9.80+171.5%+95.2%$329.16M$50.58M-8.02160Analyst ForecastAnalyst RevisionNews CoverageGap DownTNGXTango Therapeutics1.8563 of 5 stars$3.06flat$13.14+329.5%-68.5%$328.70M$43.38M-2.5990News CoverageSAGESage Therapeutics4.1504 of 5 stars$5.22-3.2%$11.53+120.9%-73.1%$319.31M$86.46M-0.97690JSPRJasper Therapeutics2.3297 of 5 stars$21.00+1.9%$73.38+249.4%+290.1%$315.02MN/A-4.3520Positive NewsVALNValneva2.1517 of 5 stars$3.84-2.3%$18.50+381.8%-62.2%$312M$165.52M-30.23700News CoverageHigh Trading VolumeFDMT4D Molecular Therapeutics2.5905 of 5 stars$6.61+1.7%$42.13+537.3%-66.9%$305.57M$17,000.00-2.28201Analyst ForecastCCCCC4 Therapeutics2.0607 of 5 stars$4.32-1.4%$10.00+131.5%-9.2%$304.94M$33.67M-2.58150Analyst UpgradeNews CoveragePositive News Related Companies and Tools Related Companies Trevi Therapeutics Alternatives Eton Pharmaceuticals Alternatives Canopy Growth Alternatives Aquestive Therapeutics Alternatives Tango Therapeutics Alternatives Sage Therapeutics Alternatives Jasper Therapeutics Alternatives Valneva Alternatives 4D Molecular Therapeutics Alternatives C4 Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:QNCX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QNCX Stock Alerts